Navigation Links
NOVIS Announces Appointment of John J. Arlotta as Chairman
Date:10/23/2008

MIAMI, Oct. 23 /PRNewswire/ -- NOVIS Pharmaceuticals, Inc. today announced that healthcare industry veteran John J. Arlotta has been appointed Chairman of the Board. The appointment was announced during the most recent NOVIS Board of Directors meeting and is effective immediately.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081023/CLTH043LOGO )

"I am very excited to take on this role at NOVIS, and I look forward to helping the company achieve its aggressive strategic goals," said Mr. Arlotta. He added, "I am also very impressed with the management team that has been assembled at NOVIS, and I am excited to have the opportunity to assist them in achieving their vision for the company."

Thomas E. Burke III, President and CEO of NOVIS, said, "We are thrilled and honored to have John join our team. John's career has been exemplified by dramatic growth and an unwavering commitment to patient safety and customer service. I look forward to working with John as we create new partnerships, expand our product line, and further establish NOVIS as the vendor of choice for specialty therapeutics."

Mr. Arlotta has more than 30 years experience in the pharmacy services industry, most recently as Chairman, President and CEO of Coram Inc., a leading provider of specialty infusion and pharmacy distribution services that was acquired by Apria Healthcare Group in December 2007. Previously, he served as the President and CEO of NeighborCare, a Baltimore based public company and provider of pharmaceutical products and services to nursing homes. Mr. Arlotta's experience also includes five years as President and COO of Caremark Rx, ten years as owner and manager of HealthCall, and fifteen years at Baxter International. Mr. Arlotta is a graduate of the University of Notre Dame, is married with three adult children and currently lives in Denver, Colorado. In 2008, Mr. Arlotta purchased the Minnesota Swarm professional indoor lacrosse franchise.

About NOVIS Pharmaceuticals, Inc.

NOVIS Pharmaceuticals is a leading distributor of specialty therapeutics. Through superior customer service and innovative technology solutions, the company provides safe, timely and economical access to critical medications. Based in Miami, FL, and supported by strategically located centers throughout the U.S. and Puerto Rico, NOVIS is a privately held company. For more information, please visit http://www.novispharma.com .


'/>"/>
SOURCE NOVIS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Renovis to Present at CIBC World Markets Healthcare Conference
2. Renovis Reports Third Quarter 2007 Financial Results
3. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
4. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
5. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
6. Evotecs Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective
7. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
8. Proxy Governance and Egan-Jones Recommend Renovis Shareholders Vote For Merger With Evotec
9. Renovis Stockholders Approve Acquisition by Evotec
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... BOUNTIFUL, Utah (PRWEB) , ... May 24, 2017 ... ... announces the selection and implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery ... a key component of a $24 million plant upgrade to sustainably meet current ...
(Date:5/24/2017)... ... 23, 2017 , ... Federal funding for basic and applied scientific research — ... and other vital technologies — deserves continued support, say leaders of SPIE, the ... today in responding to the President’s budget request for Fiscal Year 2018. , The ...
(Date:5/24/2017)... , May 23, 2017 As Ebola resurfaces in ... four deaths and 20 suspected cases now reported, a new ... PubMed database, showed a correlation between the 2014 and 2017 ... counts rose sharply in 2012-13, which preceded the 2014 outbreak. ... the Ebola gene Replikin counts in 2014-15, which again precedes ...
(Date:5/23/2017)... ... , ... A recent survey conducted by the Weed Science Society of America ... 12 categories of broadleaf crops, fruits and vegetables, while common lambsquarters ranks as the ... participated in the 2016 survey, the second conducted by WSSA. A 2015 baseline ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
Breaking Biology News(10 mins):